Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Argent Biopharma ( (AU:RGT) ) has issued an announcement.
Argent BioPharma has issued 5,616,000 fully paid ordinary shares, taking advantage of an exemption under section 708A(5) of the Corporations Act 2001, which allows for the on-sale of securities without disclosure. This strategic move aligns with the company’s compliance with relevant legal provisions and supports its ongoing efforts to advance its clinical programs and strengthen its market position in the biopharmaceutical industry.
More about Argent Biopharma
Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company focused on developing nano-engineered medicines that address the balance between the nervous and immune systems. The company’s lead candidates, CannEpil® and CimetrA®, are aimed at treating drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders. Argent BioPharma utilizes proprietary delivery platforms to enhance drug efficacy and is committed to addressing urgent unmet needs in central nervous system and systemic inflammation.
Average Trading Volume: 78,705
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.44M
For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.